Krystal Biotech Files Response With USPTO on KB801 Patent Application; Discontinues Clinical Study To Advance KB801 Into Pivotal Trial; No Safety Concerns Observed; No Further Subject-level Updates From Discontinued Study; Pivotal Trial Results Expected In Due Course
Benzinga Newsdesk 3 months ago
News
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001711279/000171127926000050/krys-20260721.htm